Working... Menu

Oxytocin in MRI-HIFU

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03937401
Recruitment Status : Enrolling by invitation
First Posted : May 3, 2019
Last Update Posted : May 3, 2019
Information provided by (Responsible Party):
Turku University Hospital

Brief Summary:
Capability of oxytocin in improving the efficacy of MRI-HIFU is studied. Patients undergoing MRI-HIFU treatment are given oxytocin during treatment and the efficacy of the treatment will be analysed by patient reported symptom questionnaires and imaging data.

Condition or disease Intervention/treatment Phase
Fibroid Adenomyosis Drug: Oxytocin Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Use of Oxytocin in MRI-HIFU Treatment
Actual Study Start Date : February 1, 2019
Estimated Primary Completion Date : December 30, 2019
Estimated Study Completion Date : January 1, 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Oxytocin

Arm Intervention/treatment
Experimental: Patients treated with oxytocin during MRI-HIFU Drug: Oxytocin
Oxytocin infusion during MRI-HIFU treatment
Other Name: MRI-HIFU

Primary Outcome Measures :
  1. NPV [ Time Frame: up to one year ]
    non perfused volume (percentage of fibroid destroyed)

  2. duration of MRI-HIFU [ Time Frame: up to one year ]
    duration of MRI-HIFU treatment

  3. UFS-Qol [ Time Frame: 12 months after HIFU treatment ]
    Uterine fibroid symptom severity and quality of life (patient quality of life questionnaire)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Patients undergoing MRI-HIFU -treatment
  • Patients assessed for suitability to MRI-HIFU treatment
  • willingness to participate in trial

Exclusion Criteria:

  • Known allergy to Syntocinon/oxytocin
  • Elevated blood pressure
  • ischemic heart disease
  • Long QT- interval

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03937401

Layout table for location information
Turku University Hospital
Turku, Finland, 20521
Sponsors and Collaborators
Turku University Hospital

Layout table for additonal information
Responsible Party: Turku University Hospital Identifier: NCT03937401     History of Changes
Other Study ID Numbers: T366/2017
First Posted: May 3, 2019    Key Record Dates
Last Update Posted: May 3, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Individual participant data will not be shared with other researchers

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Turku University Hospital:

Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Uterine Diseases
Genital Diseases, Female
Reproductive Control Agents
Physiological Effects of Drugs